Otros idiomas Revive Therapeutics Ltd.

Acciones

RVV

CA7615161030

Mercado cerrado - Canadian Securities Exchange Otros sitios de cotización 19:23:32 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
0,03 ^CAD	+20,00 %		0,00 %	0,00 %

18/04	Revive Therapeutics Ltd. Anuncia la aceptación por la FDA de la solicitud de reunión para el producto de diagnóstico COVID largo	CI
02/04	Revive Therapeutics Ltd. Proporciona información actualizada sobre el estudio clínico con psilocibina para el trastorno por consumo de metanfetamina	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

FDA Grants Revive Therapeutics Type C Meeting Request For Bucillamine Study to Treat Long COVID	23/04
Revive Therapeutics Brief: Announcing Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID	23/04
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID	23/04
Revive Therapeutics Announced FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	18/04
Revive Therapeutics Brief: Announcing FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	18/04
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	18/04
Revive Therapeutics Ltd. Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	18/04
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	02/04
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	02/04
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	02/04
Revive Therapeutics Ltd. Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	02/04
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	27/03
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	27/03
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	27/03
Revive Therapeutics : Document	20/03
Revive Therapeutics : Document	20/03
Revive Therapeutics to Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID	19/03
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID	19/03
Revive Therapeutics Ltd. Announces to Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID	19/03
Revive Therapeutics Provides Corporate Update	12/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Revive Therapeutics Ltd.

Acciones

RVV

CA7615161030

Otros idiomas

Filtros